IDH1(R132H) Immunoexpression in Glioma
DOI:
https://doi.org/10.56056/amj.2018.43Keywords:
IDH1, Immunohistochemistry, GliomaAbstract
Background and objectives: Gliomas are the most common type of primary brain tumors. They result from accumu-- lation of multiple genetic alterations. Isocitrate dehydrogenase 1 mutations are detected in gliomas. This study aimed to assess IDH1 immunoexpression in different types of gliomas and to correlate the results with patient’s age, gender, tumor site, tumor type and grade.
Methods:During the period from January 2015 –January 2017, 97 cases of gliomas were collected from Rizgary Teaching Hospital and private laboratories in Erbil city. Typing and grading of tumors were done according to World Health Organization classification of brain tumors 2007.Immunohistochemical staining was done for IDH1 using monoclonal Antibody IDH1R132.
Results: Out of 97 cases of gliomas; 16 were grade I, 27 were grade II, 10 were anaplastic gliomas grade III and 44 cases were glioblastomas; grade IV. Positive IDH1 immunoex- pression was observed in 36 (37.1%) cases of gliomas. The highest prevalence of IDH1 was found in the age group 30-44 years (52.8%), in supratentorial tumors (44.3%) and in grade II and III astrocytoma (72.2% and 75%).Highly significant correlation was found between Isocitrate dehydrogenase 1 expression and age of the patients, tumor type and grade while a significant correlation was found between Isocitrate dehydrogenase 1 expression and tumor site.
Conclusions:Our study concluded that Isocitrate dehydrogenase 1 is 36 (37.1%) expressed in gliomas and it is sig- nificantly associated with patient’s age, tumor site, histological type and grade, thus it may act as a good diagnostic and prognostic marker for gliomas.
Downloads
References
Louis DN, Ohgaki H, Wiestler OW, Cavenee WK, Burger PC, Jouvet A, et al.The2007 WHO Classification of Tumors of the Central Nervous System. Acta Neuropathol. 2007; 114(2):97–109.
Sipayya V, Sharma Ira, Sharma KC, Singh A. Immunohistochemical expression of IDH1in gliomas: A tissue microarray-based approach. J of Cancer Res and Therap.2012;8(4):598-601.
Stupp R, Mason WP, Van den Bent MJ, Weller M,FisherB,Taphoorn M. J.B, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med.2005; 352:987-96.
Wen PY, Kesari S. Malignant gliomas in adults.NEngl J Med.2008;359:492-507.
Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, DiPatre PL, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64: 6892-9.
Guo C, Pirozzi CJ, Lopez GY, H Yan. Isocitrate dehydrogenase muta- tions in gliomas: mechanisms, biomarkers and therapeutic target. Curr Opin Neurol. 2011; 24:648–52.
Toedt G, Barbus S, Wolter M, Felsberg J, Tews B, Blond F, et al. Molec- ular signatures classify astrocyticgliomas by IDH1 mutation status. Int J Cancer. 2011;128:1095–1103.
Thota B, Shukla SK, Srividya MR, Shwetha SD, Arivazhgan A, Then- narasu K, et al. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical rele- vance. Am J ClinPathol. 2012;138:177–84.
Thompson CB.Metabolic enzymes as oncogenes or tumor suppres- sors. N Engl J Med. 2009;360:813–15.
Saeed MS. IDH1 Mutation in Gliomas in Mosul City – IraqMacedJ- MedSci. 2015,15; 3(2):250-55.
Bigner SH, Matthews MR, Rasheed BKA, Wiltshire RN, Friedman HS, Friedman AH, et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999;155:375-86.
Horbinski C, Kofler J, Yeaney G, Camelo-Piragua S, Venneti S, Louis DN, et al. Isocitrate dehydrogenase 1 analysis differentiates ganglio- gliomas from infiltrative gliomas. Brain Pathol 2011;21: 564–74.
Piragua SC, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL. Mutant IDH1-specificimmunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 2010;119: 509–11.
Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, et al. IDH1 mutations at residue p.R132 (IDH1(R132) occur fre- quently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009;30:7–11.
Joseph NM, Phillips J, Dahiya S, Felicella M, Tihan T, Brat DJ, Per- ry A.IDH1 and OLIG2 expression in glioblastomavariants. Mod Pathol. 2013; 26:315–26.
Parsons DW, Jones S, Zhang X, Cheng-Ho Lin J, Leary RJ, An- genendt P, et al. An integrated genomic analysis of human glioblasto- mamultiforme. Science 2008;321:1807–12.
Yusoff A, Zulfakhar FN, Sul’ain MD, Idris Z, Abdullah JM. Association of the IDH1 C.395G>A (R132H) Mutation with Histological Type in Malay Brain Tumors.Asian Pac J Cancer Prev. 2016; 17(12): 5195–201.
Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, YamashitaY, Suzuki H, Tominaga T, et al. Analysis of IDH1 and IDH2 mutations in Japanese gliomapatients. Cancer Sci. 2009;100:1996-8.
Qi ST, Yu L, Lu YT, Ou YH, Li ZY, Wu LX,et al. IDH mutations occurfrequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. Oncol Rep. 2011;26:1479–85.
Myung JK, Cho HJ, Park CK, Kim SK, Phi JH, Park SH. IDH1 mutation of gliomas with long-term survival analysis. Oncol Rep. 2012;28:1639– 44.
Mukasa A, Takayanagi S, Saito K, Shibahara U, Tabei Y, Furuya K, et al. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci. 2012;103:587–92.
Qi S, Yu L, Li H, Ou Y, Qiu X, Ding Y,et al. Isocitrate dehydroge- nase mutation is associated with tumor location and magnetic reso- nance imaging characteristics in astrocytic neoplasms. Oncol Lett. 2014;7:1895–1902.
Wang HY, Tang K, Liang TY ,Zhang WZ, LiJ Y, Wang W, et al. The com- parison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas. J Exp Clin Cancer Res. 2016;35:86.
Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendroglio- mas. Am J Pathol.2009; 174:1149-53.
Robinson C, Kleinschmidt-DeMasters BK. IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over. J Neuropathol Exp Neurol. 2017 Feb 1;76(2):151-54.
Yan W, Zhang W, You G, Bao Z, Wang Y, Liu Y, et al. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in pri- mary glioblastoma: a report of 118 patients from China. PLOS One. 2012;7:30339.
Fouad EM, Saba EEI, Rashed MEH. Abdelwahab RM. Evaluation of the role of mutatant, EGFR and BCL2 protien expression in distinguish- ing diffuse astrocytoma from astrocytosis. ZUMJ.2014. 20(3),404-13.
Capper D, Weißert S, Balss J, Habel A, Meyer J, Jäge D, et al. Char- acterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors. Brain Pathol.2010; 20;245-54.
Agrawal S, Sharma MC, Jha P, Pathak P, Suri V, Sarkar C, et al.Com- parative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.Neuro-Oncology 2016, 15(6);718-26.
Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, et al. IDH1 mutations are present in the majority of common adult gliomas but are rare in primary glioblastomas. NeuroOncol. 2009; 11:341-47.
Hartmann Ch, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: im- plications for classification of gliomas. Acta Neuropathol.2010; 120(6); 707-18.
Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas. AACR journal.2009;15(19):6002-7.
Dwianingsih EK, , Bawono RG , Rhamadianti AF, Bayuangga HF, Mal- ueka RG. Correlation between grading and IDH1 mutation in Indonesian glioma. Jour of NeurolSci. 2017;381:386–87.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Nyan Saeed Omer, Jalal Ali Jalal , Ava Tahir Ismael
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in AMJ (The Scientific Journal of Kurdistan Higher Council of Medical Specialties )is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0)
